| Misonix to Present at the Sanders Morris Harris Middle Market Investor Growth Conference |
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Oct. 19, 2006--Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that it has been invited to present at the Sanders Morris Harris Middle Market Investor Growth Conference. The conference is being held on October 23-24, 2006, at the Omni Berkshire Place Hotel in New York and will be attended by securities analysts, fund managers and institutional investors. Misonix management will present on Tuesday, October 24, at 2:30 PM Eastern time, which will be followed by a breakout session. The event is intended to showcase approximately 80 companies during the two day event. Presenting companies were selected by Sanders Morris Harris' equity research team and other executives and are representative of the healthcare, technology, energy, consumer, and financial services sectors. Sanders Morris Harris Investment Banking (www.smhib.com) is headquartered in New York with regional offices in Los Angeles and Houston. The firm is a full-service investment bank providing middle-market companies with private placements and public offerings of equity and debt securities, as well as financial-advisory services in connection with mergers and acquisitions, restructuring and recapitalizations. Sanders Morris Harris is led with the same entrepreneurial spirit as the firm's clients, and offers all of the advantages of a full-service, middle-market investment firm delivered by experienced senior bankers to optimally serve clients. About Misonix: Misonix designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com. With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
CONTACT: Misonix |